Tailoring Treatment Approaches in Psoriasis Management - Episode 7
Learnings From the VISIBLE Study in Skin of Color
Panelists discuss how despite limited but encouraging efficacy and safety data from studies like VISIBLE (guselkumab) and various subgroup analyses supporting biologic use across diverse skin tones, clinicians must still consider unique presentations and concerns when treating patients with skin of color, including postinflammatory hyperpigmentation, follicular presentation patterns, cultural perspectives on treatment, and historical underrepresentation in clinical trials, while emphasizing the importance of personalized discussions about treatment expectations and outcomes specific to different skin phototypes.
Video content above is prompted by the following:
- Data, while limited, show that biologics are safe and effective treatment options across skin tones. How do you take these data into consideration when deciding on treatment for your patients with skin of color?
- VISIBLE study—guselkumab
- Various subgroup and post hoc analyses
